Article -> Article Details
| Title | Vietnam Biosimilar Market Size, Share, Trends, Growth and Forecast Report 2025-2033 |
|---|---|
| Category | Fitness Health --> Health Articles |
| Meta Keywords | Vietnam Biosimilar Market |
| Owner | akshaykumar |
| Description | |
| Market Overview The Vietnam Biosimilar Market was valued at USD 106.00 Million in 2024 and is forecasted to reach USD 747.04 Million by 2033. Exhibiting a robust CAGR of 24.23% during the forecast period 2025-2033, the market is rapidly evolving. This growth is driven by rising demand for affordable biologic therapies in chronic, autoimmune, and oncology indications, supported by enhanced government backing, improved healthcare infrastructure, and evolving manufacturing capabilities across Vietnam. Study Assumption Years
Vietnam Biosimilar Market Key Takeaways
Sample Request Link: https://www.imarcgroup.com/vietnam-biosimilar-market/requestsample Market Growth Factors The Vietnamese government streamlines regulations and harmonizes guidelines to aid biosimilar market growth. Circular 12/2025/TT-BYT of the Vietnamese Ministry of Health, effective since July 1, 2025, outlines registration pathways for biosimilars, including acceptance of Certificates of Pharmaceutical Product (CPPs) under recognized regulatory authorities. This, in combination with clinical record keeping, differentiated timelines for review, and the issuance of Decision 16/QĐ-K2ĐT for nonclinical and clinical tests in a manner consistent with international standards for safety and efficacy, reduces uncertainty and encourages investor interest. Further growth is catalyzed by innovation or market entry and approval of new products. For example, an autoimmune disease product entered the market by June 2025 and a treatment biosimilar for breast and stomach cancer came to market by August 2025. These launches show the growing demand of low-cost biologics for chronic diseases, autoimmune diseases, and cancers. Vietnam's regulatory framework improvements, and regional licensing agreements make it a competitive option for biosimilars companies, and increase therapeutic options for public and private healthcare sectors. On the domestic front, Vietnam seeks to improve technology transfer and local production by 2030 through national action plans, including legal instruments such as health insurance reimbursement and fair market competition for domestic biologics. The Drug Administration of Vietnam (DAV) concretely guided and strengthened the country's biosimilar framework. Regulatory training and laboratory capacity improve. Dossier review streamlines. Time to market reduces while a sustainable local biosimilars supply chain is established. Market Segmentation
The market includes these molecules, each representing biosimilar products focusing on various therapeutic applications with detailed market analysis provided.
The report analyzes biosimilar demand and usage across these medical indications, reflecting the diversified patient needs in Vietnam.
Detailed analysis covers biosimilar production through in-house capabilities and outsourced contract manufacturing, reflecting industry manufacturing trends.
The market is segmented regionally for comprehensive assessment of biosimilar adoption and growth dynamics across these major Vietnamese regions. Regional Insights Northern Vietnam, Central Vietnam, and Southern Vietnam constitute the main regional markets. Specific market share or CAGR statistics per region are not provided in the source. However, the report includes comprehensive regional segmentation to analyze market distribution and growth potentials across the country. Recent Developments & News In August 2025, Vietnam-headquartered Sandoz entered a licensing agreement with Lupin Limited for marketing a biosimilar across multiple markets, including the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Sandoz will handle commercialization while Lupin manages manufacturing and regulatory submissions. Marketing rights are generally exclusive except for semi-exclusive rights in France, Australia, Vietnam, and Malaysia, signaling expanded biosimilar collaborations and market reach for Vietnam. Competitive Landscape The competitive landscape of the industry has also been examined along with the profiles of the key players. If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization. Request For Customization: https://www.imarcgroup.com/request?type=report&id=42798&flag=E About Us IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research. Contact Us IMARC Group, 134 N 4th St. Brooklyn, NY 11249, USA, Email: sales@imarcgroup.com, Tel No: (D) +91 120 433 0800, United States: +1-201971-6302 | |